Abstract:In recent studies, vibration-controlled transient elastography (FibroScan) has been reported as an alternative noninvasive approach for measuring liver steatosis and fibrosis. The present study aimed to investigate the feasibility of FibroScan controlled attenuation parameter (CAP) and liver stiffness measurement (LSM) in the detection of increased arterial stiffness in asymptomatic populations in China. A retrospective cohort recruiting 4747 asymptomatic patients with no underlying causes of liver disease and having FibroScan and brachial-ankle pulse wave velocity (baPWV) during wellness check-up was covered. Nonalcoholic fatty liver disease (NAFLD) was defined as a CAP >= 238 dB/m. NAFLD with significant fibrosis was defined as an LSM >= 7.3 kPa in the presence of NAFLD. Increased arterial stiffness was determined as a BaPWV >= 1.4m/second. Among the 4747 study participants, 1596 subjects (33.6%) suffered from increased arterial stiffness. The prevalence of increased arterial stiffness progressively increased across CAP quartiles and LSM quartiles in NAFLD (23.5%, 30.8%, 38.3%, 43.7%, P < .001 and 33.1%, 36.8%, 40.4%, 48.2%, P < .001, respectively). After conventional cardiovascular risk factors were adjusted (age, sex, overweight, diabetes mellitus, hypertension, hypercholesterolemia, and current smoking habits), multivariate logistic regression analysis revealed that CAP (odd ratio [OR] = 1.005; 95% confidence interval [CI]: 1.003-1.006; P < .001), NAFLD (OR = 1.427; 95% CI: 1.212-1.681; P < .001), LSM in NAFLD (OR = 1.073; 95% CI: 1.023-1.125; P = .003), and significant fibrosis in NAFLD (OR = 1.480; 95% CI: 1.090-2.010; P = .012) were independently associated with increased arterial stiffness. Furthermore, in a multivariate logistic regression analysis, OR (95% CI) for the maximal vs. the minimal quartile of CAP was 1.602 (1.268-2.024), and that of LSM in NAFLD was 1.362 (1.034-1.792) after adjustment for the above-mentioned risk factors. Notably, NAFLD and significant fibrosis in NAFLD were significantly correlated only with increased arterial stiffness in subjects without hypertension or diabetes mellitus after adjustment for the above-mentioned risk factors. CAP-defined NAFLD and LSM-defined significant fibrosis in NAFLD showed significant and independent relationships with increased arterial stiffness even after adjustment for conventional cardiovascular risk factors, which can be conducive to stratifying relative risk of subjects having undergone screening assessment for cardiovascular disease.

Effect of food intake on the accruacy of controlled attenuation parameter in diagnosis of patients with liver steatosis by Fibroscan

Controlled attenuation parameter for steatosis assessment in health checkup groups

Controlled Attenuation Parameter by VCTE for Steatosis Assessment in Health Check Public with Reference to MRI-PDFF.

Usefulness Of Controlled Attenuation Parameter And Liver Stiffness Measurement For Detecting Increased Arterial Stiffness In Asymptomatic Populations In China

Value of FibroScan in the Detection of Controlled Attenuation Parameters for Fatty Liver Disease

Influential factors and clinical value of controlled attenuation parameters in the evaluation of hepatic steatosis using FibroScan?

Controlled Attenuation Parameter for Non-Invasive Assessment of Hepatic Steatosis in Chinese Patients

Transient Elastography in Alcoholic Liver Disease and Nonalcoholic Fatty Liver Disease: A Systemic Review and Meta-Analysis

Multivariable regression analysis of controlled attenuation parameter of liver by FibroScan in healthy in-dividuals

Controlled attenuation parameter by vibration-controlled transient elastography for steatosis assessment in members of the public undergoing regular health checkups with reference to magnetic resonance imaging-based proton density fat fraction

[A Multi-Center Clinical Study of a Novel Controlled Attenuation Parameter for Assessment of Fatty Liver].

Research progress in controlled attenuation parameter for assessment of fatty liver disease

The Efficacy of Anthropometric Indicators in Predicting Non-Alcoholic Fatty Liver Disease Using FibroScan® CAP Values among the Taiwanese Population

Reproducibility study of Fibroscan for liver controlled attenuator parameters measurement

Diagnostic Accuracy of Controlled Attenuation Parameter (CAP) As a Non-Invasive Test for Steatosis in Suspected Non-Alcoholic Fatty Liver Disease: a Systematic Review and Meta-Analysis

Impact of Skin Capsular Distance on the Performance of Controlled Attenuation Parameter in Patients with Chronic Liver Disease

A meta-analysis on the diagnostic performance of magnetic resonance imaging and transient elastography in nonalcoholic fatty liver disease

Validation of Controlled Attenuation Parameter Measured by FibroScan as a Novel Surrogate Marker for the Evaluation of Metabolic Derangement

Relationship between liver controlled attenuation parameters and body fat mass and its distribution

A new visual quantitative assessment of ultrasound attenuation parameters for the mild liver steatosis

A Novel Non-Invasive Index for the Prediction of Liver Fibrosis in Chronic Hepatitis B Patients with Concurrent Nonalcoholic Fatty Liver Disease